Effects of rTMS on three cortical areas in Parkinson’s Disease
Objective: To evaluate the role of rTMS over primary motor area, premotor area, supplementary motor area in Parkinsons Disease. Background: Parkinson’s disease (PD) presents with…Objective analysis of walking tremor in Parkinson’s disease: A spectrum of classical rest tremor?
Objective: To delineate objective characteristics of walking tremor in PD patients in relation to classical parkinsonian rest tremor with inertial sensors. Background: Tremors in PD…Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone (OPC)…Putative treatment of Parkinson’s Disease using extract of Bacopa monnieri
Objective: Bacopa monnieri is largely treasured as a revitalizing herb used by Ayurvedic medical practitioners for almost 3000 years. The herb has been mentioned in…Effects of Intensive Voice and Articulation Treatments on Voice Quality in Parkinson’s disease
Objective: This study evaluated the impact of voice treatment (LSVT LOUD) and articulation treatment (LSVT ARTIC) on voice quality in Parkinson's disease (PD) measured by…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials
Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy
Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…Reduction of neuroinflammation by selective inhibition of the N-type calcium channel is beneficial in various animal models of neurodegeneration, here in the SOD1G93A transgenic mouse model of ALS
Objective: Neuroinflammation is a pathological hallmark of several neurodegenerative diseases. We speculated that reduction of calcium ion influx specifically in neurons should reduce inflammatory cellular…
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 177
- Next Page »